Ignite Creation Date:
2025-12-24 @ 9:54 PM
Ignite Modification Date:
2026-03-10 @ 6:18 PM
Study NCT ID:
NCT02511132
Status:
COMPLETED
Last Update Posted:
2022-12-22
First Post:
2015-07-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Sponsor:
Gradalis, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-02-10
Start Date Type:
ACTUAL
Primary Completion Date:
2018-11-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-12-23
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-28
First Submit QC Date:
None
Study First Post Date:
2015-07-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-04-27
Results First Submit QC Date:
None
Results First Post Date:
2022-07-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-12-20
Last Update Post Date:
2022-12-22
Last Update Post Date Type:
ACTUAL